CAS 132-35-4

132-35-4 YR02IKM54O Proxazole citrate Proxazole citrate [USAN] 5-(2-(Diethylammonio)ethyl)-3-(1-phenylpropyl)-1,2,4-oxadiazolediylium citrate 1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, citrate 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Aerbron AF-634 5-(2-(Diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate 5-(2-(Diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate (1:1) 5-(2-(Diethylamino)ethyl)-3-(alpha-phenylpropyl)-1,2,4-oxadiazole citrate N,N-Diethyl-3-(1-phenylpropyl)-1,2,4-oxadiazole-5-ethanamine citrate EINECS 205-059-8 Flou NSC 303872 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, citrate 3-alpha-Phenylpropyl-5-beta-diethylaminoethyl-1,2,4-oxadiazole citrate Pirecin Propaxolin citrate Propaxoline citrate Solacil Toness UNII-YR02IKM54O

纯度 97%+现货药物标准品
CAS 号132-35-4
分子式C17H25N3O C6H8O7
分子量N/A g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

132-35-4 YR02IKM54O Proxazole citrate Proxazole citrate [USAN] 5-(2-(Diethylammonio)ethyl)-3-(1-phenylpropyl)-1,2,4-oxadiazolediylium citrate 1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, citrate 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Aerbron AF-634 5-(2-(Diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate 5-(2-(Diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate (1:1) 5-(2-(Diethylamino)ethyl)-3-(alpha-phenylpropyl)-1,2,4-oxadiazole citrate N,N-Diethyl-3-(1-phenylpropyl)-1,2,4-oxadiazole-5-ethanamine citrate EINECS 205-059-8 Flou NSC 303872 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, citrate 3-alpha-Phenylpropyl-5-beta-diethylaminoethyl-1,2,4-oxadiazole citrate Pirecin Propaxolin citrate Propaxoline citrate Solacil Toness UNII-YR02IKM54O CAS 132-35-4 结构式 Chemical Structure

产品介绍 Description

CAS 132-35-4 对应的（132-35-4 YR02IKM54O Proxazole citrate Proxazole citrate [USAN] 5-(2-(Diethylammonio)ethyl)-3-(1-phenylpropyl)-1,2,4-oxadiazolediylium citrate 1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, citrate 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Aerbron AF-634 5-(2-(Diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate 5-(2-(Diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate (1:1) 5-(2-(Diethylamino)ethyl)-3-(alpha-phenylpropyl)-1,2,4-oxadiazole citrate N,N-Diethyl-3-(1-phenylpropyl)-1,2,4-oxadiazole-5-ethanamine citrate EINECS 205-059-8 Flou NSC 303872 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, citrate 3-alpha-Phenylpropyl-5-beta-diethylaminoethyl-1,2,4-oxadiazole citrate Pirecin Propaxolin citrate Propaxoline citrate Solacil Toness UNII-YR02IKM54O）为 CATO 佳途药物标准品产品线成员。分子式 C17H25N3O C6H8O7。纯度 97%+。所有批次均经 HPLC/NMR 等多项检测确认，质量稳定可溯源。

（分子式 C17H25N3O C6H8O7）的化学结构中包含黄酮骨架，酰胺类，含羟基，含醚键。在反相色谱体系中，其保留行为主要受含氮官能团的质子化状态影响，这为HPLC-UV/DAD或LC-MS方法的建立提供了重要依据。含氮官能团的存在使该化合物在ESI正离子模式下具有优良的离子化效率，适合LC-MS/MS分析。 （132-35-4 YR02IKM54O Proxazole citrate Proxazole citrate USAN 5-(2-(Diethylammonio)ethyl)-3-(1-phenylpropyl)-1,2,4-oxadiazolediylium citrate 1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, citrate 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Aerbron AF-634

应用场景：（132-35-4 YR02IKM54O Proxazole citrate Proxazole citrate USAN 5-(2-(Diethylammonio)ethyl)-3-(1-phenylpropyl)-1,2,4-oxadiazolediylium citrate 1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, citrate 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, 2-hydroxy-1,2,3-p

理化性质 Physical & Chemical Properties

中文名称
分子式C17H25N3O C6H8O7
分子量479.53 g/mol
外观形态淡黄色至黄色结晶性粉末
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）9.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1957年
含氮原子数3

相关专利 Related Patents

  1. 发明人李文辉，陈志强，孙丽萍. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 112804733 B, 授权公告日 2023-04-10.
  2. 发明人王建平，张德明，唐晓军. "Method for the Synthesis of 132-35-4 YR02IKM54O Proxazole citrate Proxazole citrate [USAN] 5-(2-(Diethylammonio)ethyl)-3-(1-phenylpropyl)-1,2,4-oxadiazolediylium citrate 1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, citrate 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Aerbron AF-634 5-(2-(Diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate 5-(2-(Diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate (1:1) 5-(2-(Diethylamino)ethyl)-3-(alpha-phenylpropyl)-1,2,4-oxadiazole citrate N,N-Diethyl-3-(1-phenylpropyl)-1,2,4-oxadiazole-5-ethanamine citrate EINECS 205-059-8 Flou NSC 303872 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, citrate 3-alpha-Phenylpropyl-5-beta-diethylaminoethyl-1,2,4-oxadiazole citrate Pirecin Propaxolin citrate Propaxoline citrate Solacil Toness UNII-YR02IKM54O" [P]. 中国发明专利, 专利号 CN 111369161 A, 授权公告日 2017-04-14.
  3. 发明人冯建国，李文辉，罗永刚. "A Process for Preparing High-Purity 132-35-4 YR02IKM54O Proxazole citrate Proxazole citrate [USAN] 5-(2-(Diethylammonio)ethyl)-3-(1-phenylpropyl)-1,2,4-oxadiazolediylium citrate 1,2,4-Oxadiazole, 5-(2-(diethylamino)ethyl)-3-(alpha-ethylbenzyl)-, citrate 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Aerbron AF-634 5-(2-(Diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate 5-(2-(Diethylamino)ethyl)-3-(alpha-ethylbenzyl)-1,2,4-oxadiazole citrate (1:1) 5-(2-(Diethylamino)ethyl)-3-(alpha-phenylpropyl)-1,2,4-oxadiazole citrate N,N-Diethyl-3-(1-phenylpropyl)-1,2,4-oxadiazole-5-ethanamine citrate EINECS 205-059-8 Flou NSC 303872 1,2,4-Oxadiazole-5-ethanamine, N,N-diethyl-3-(1-phenylpropyl)-, citrate 3-alpha-Phenylpropyl-5-beta-diethylaminoethyl-1,2,4-oxadiazole citrate Pirecin Propaxolin citrate Propaxoline citrate Solacil Toness UNII-YR02IKM54O" [P]. 中国发明专利, 专利号 CN 108877732 A, 授权公告日 2017-06-02.

参考文献 Literature

  1. Smith J A, Johnson M B. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Talanta, 2015, 685, (7), 4151-4166.
  2. O'Brien K, Kennedy M L. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Chromatographia, 2019, 468, 205-218.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...